Despite being one of the most frequent chronic diseases, asthma patients live in times of hope. The introduction of regular treatment with inhaled corticosteroids (ICS) was crucial, impacting and changing the lives of several hundred million asthmatics. Advances with new molecules, whether alone or in combination, coupled with developments in inhaler technology and the advent of biologics raise the aspiration of achieving control and normalising (as opposed to optimizing) lung function, for every asthma patient. As a chronic disease without definite cure, the need for long-term real-life studies is imperative to assess clinical practice outcomes. This article is protected by copyright. All rights reserved.
|Number of pages||2|
|Journal||Allergy: European Journal of Allergy and Clinical Immunology|
|Early online date||24 Aug 2019|
|Publication status||Published - Jan 2020|